Wugen key facts
as of Oct 2026- Developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers.
- Wugen is valued at approximately $214.5M as of Oct 2026, down 12% since its later-stage round, Aug 2025, per PrivateMarketView’s mark.
- It has raised $323.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($115.0M) in Aug 2025.
- Notable investors include Fidelity Management & Research Company, Alexandria Venture Investments, Alpha Wave Global, Sands Capital, BioGenerator Ventures — 13 tracked in total.
- 4 institutional filers report fund marks on Wugen across 84 filings.
- Status: Privately Held (backing).
Down 12% since its later-stage round, Aug 2025 ($245.0M post-money).
- ·The complete investor list: 13 names
- ·Watch Wugen: the Monday email on marks, rounds and moves
Institutional fund marks on Wugen
4 filers · latest Jul 20264 SEC-registered funds reported 84 fair-value marks on Wugen between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Wugen funding rounds
2 roundsWho backs Wugen
13+Wugen valuation
Wugen is valued at approximately $215 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Aug 2025, at a $245 million post-money valuation; the current figure is down 12% since.
Recent activity
In the last 90 days, Wugen's record added 12 institutional fund marks (latest period Jul 2026).
How much has Wugen raised?
Wugen has raised $323 million across 2 recorded rounds since 2022. The largest was a $172 million Series B in Dec 2022; the most recent was an $115 million Series C in Aug 2025.
Institutional holders and vehicles
4 SEC-registered funds reported 84 fair-value marks on Wugen between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Wugen investors
13 investors are on record for Wugen, including Fidelity Management & Research Company, Alexandria Venture Investments, Alpha Wave Global and Sands Capital. By type, the record holds 2 venture capital firms, 2 growth equity firms and 1 asset manager. The Series C in Aug 2025 drew 4 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Convergent Therapeutics ($280 million), Artios ($260 million) and Edison Scientific ($255 million).
About Wugen
Developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers. The company's technology offers engineered memory natural killer (NK) and CAR-T cell therapies derived from healthy donors, enabling clinicians to access consistent, ready-to-use treatments that reduce production time and support broader patient access.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2018
- Employees
- 64
- Website
- wugen.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.